YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA mo...

Full description

Bibliographic Details
Main Authors: Ganglin Su, Tianshu Liu, Xiaohong Han, Hao Sun, Wenan Che, Kun Hu, Junwen Xiao, Yanfeng Li, Yuchen Liu, Wujiao Li, Hongbing Mei
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/full
id doaj-6d5cecdcb4ad45769a32d278a6364d80
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Ganglin Su
Ganglin Su
Ganglin Su
Ganglin Su
Tianshu Liu
Xiaohong Han
Hao Sun
Hao Sun
Hao Sun
Wenan Che
Kun Hu
Kun Hu
Kun Hu
Junwen Xiao
Junwen Xiao
Junwen Xiao
Yanfeng Li
Yanfeng Li
Yanfeng Li
Yuchen Liu
Yuchen Liu
Yuchen Liu
Wujiao Li
Wujiao Li
Hongbing Mei
Hongbing Mei
Hongbing Mei
spellingShingle Ganglin Su
Ganglin Su
Ganglin Su
Ganglin Su
Tianshu Liu
Xiaohong Han
Hao Sun
Hao Sun
Hao Sun
Wenan Che
Kun Hu
Kun Hu
Kun Hu
Junwen Xiao
Junwen Xiao
Junwen Xiao
Yanfeng Li
Yanfeng Li
Yanfeng Li
Yuchen Liu
Yuchen Liu
Yuchen Liu
Wujiao Li
Wujiao Li
Hongbing Mei
Hongbing Mei
Hongbing Mei
YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
Frontiers in Pharmacology
YTHDF2
KIRC
biomarker
prognosis
immune infiltrates
N6-methyladenosine (m6A) RNA methylation
author_facet Ganglin Su
Ganglin Su
Ganglin Su
Ganglin Su
Tianshu Liu
Xiaohong Han
Hao Sun
Hao Sun
Hao Sun
Wenan Che
Kun Hu
Kun Hu
Kun Hu
Junwen Xiao
Junwen Xiao
Junwen Xiao
Yanfeng Li
Yanfeng Li
Yanfeng Li
Yuchen Liu
Yuchen Liu
Yuchen Liu
Wujiao Li
Wujiao Li
Hongbing Mei
Hongbing Mei
Hongbing Mei
author_sort Ganglin Su
title YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
title_short YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
title_full YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
title_fullStr YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
title_full_unstemmed YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell Carcinoma
title_sort ythdf2 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-08-01
description Clear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.
topic YTHDF2
KIRC
biomarker
prognosis
immune infiltrates
N6-methyladenosine (m6A) RNA methylation
url https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/full
work_keys_str_mv AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT ganglinsu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT tianshuliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT xiaohonghan ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT haosun ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT wenanche ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT kunhu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT junwenxiao ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yanfengli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT yuchenliu ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT wujiaoli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT wujiaoli ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
AT hongbingmei ythdf2isapotentialbiomarkerandassociatedwithimmuneinfiltrationinkidneyrenalclearcellcarcinoma
_version_ 1717817334472638464
spelling doaj-6d5cecdcb4ad45769a32d278a6364d802021-09-03T11:45:32ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-08-011210.3389/fphar.2021.709548709548YTHDF2 is a Potential Biomarker and Associated with Immune Infiltration in Kidney Renal Clear Cell CarcinomaGanglin Su0Ganglin Su1Ganglin Su2Ganglin Su3Tianshu Liu4Xiaohong Han5Hao Sun6Hao Sun7Hao Sun8Wenan Che9Kun Hu10Kun Hu11Kun Hu12Junwen Xiao13Junwen Xiao14Junwen Xiao15Yanfeng Li16Yanfeng Li17Yanfeng Li18Yuchen Liu19Yuchen Liu20Yuchen Liu21Wujiao Li22Wujiao Li23Hongbing Mei24Hongbing Mei25Hongbing Mei26Department of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaShantou University Medical College, Shantou, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaHunan Key Laboratory of Economic Crops Genetic Improvement and Integrated Utilization, School of Life Sciences, Hunan University of Science and Technology, Xiangtan, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaDepartment of Urology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaKey Laboratory of Medical Reprogramming Technology, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaGuangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People’s Hospital, Shenzhen, ChinaClear cell renal cell carcinoma (ccRCC or KIRC) has a high mortality rate globally. It is necessary to identify biomarkers and investigate the mechanisms those biomarkers are associated with, to improve the prognosis of patients with KIRC. N6-Methyladenosine (m6A) affects the fate of modified RNA molecules and is involved in tumor progression. Different webservers were used in our research to investigate the mRNA transcription and clinical significance of YTHDF2 in KIRC. Survival analysis revealed that patients with elevated YTHDF2 transcription had a slightly longer OS and DFS than those with low YTHDF2 expression. YTHDF2 expression was shown to be significantly associated with the abundance of immune cells such as B cells, CD8+ T cells, CD4+ T cells, macrophages, neutrophils, and dendritic cells. For a series of enrichment studies, we combined information on YTHDF2-binding molecules and expression-linked genes and identified the possible influence of “mRNA surveillance pathway,” “RNA degradation,” and “RNA transport” in the biology or pathogeny of KIRC. In addition, we identified multiple miRNA, kinase, and transcription factor targets of YTHDF2 in KIRC and constructed target networks. Overall, our findings show that YTHDF2 is a possible indicator of immune infiltration in the KIRC.https://www.frontiersin.org/articles/10.3389/fphar.2021.709548/fullYTHDF2KIRCbiomarkerprognosisimmune infiltratesN6-methyladenosine (m6A) RNA methylation